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Abstract
Background: Artemisinin-based combination therapy, including artemether-lumefantrine (AL), is currently
recommended for the treatment of uncomplicated Plasmodium falciparum malaria. The objectives of the current
analysis were to compare the efficacy and safety of AL across different body weight ranges in African children, and
to examine the age and body weight relationship in this population.
Methods: Efficacy, safety and pharmacokinetic data from a randomized, investigator-blinded, multicentre trial of AL
for treatment of acute uncomplicated P. falciparum malaria in infants and children in Africa were analysed
according to body weight group.
Results: The trial included 899 patients (intent-to-treat population 886). The modified intent-to-treat (ITT)
population (n = 812) comprised 143 children 5 to < 10 kg, 334 children 10 to < 15 kg, 277 children 15 to < 25 kg,
and 58 children 25 to < 35 kg. The 28-day PCR cure rate, the primary endpoint, was comparable across all four
body weight groups (97.2%, 98.9%, 97.8% and 98.3%, respectively). There were no clinically relevant differences in
safety or tolerability between body weight groups. In the three AL body weight dosing groups (5 to < 15 kg, 15 to
< 25 kg and 25 to < 35 kg), 80% of patients were aged 10-50 months, 46-100 months and 90-147 months,
respectively.
Conclusion: Efficacy of AL in uncomplicated falciparum malaria is similar across body weight dosing groups as
currently recommended in the label with no clinically relevant differences in safety or tolerability. AL dosing based
on body weight remains advisable.
Background
Growing resistance to conventional anti-malarial drugs
and the associated resurgence in infection rates and
malaria-related morbidity and mortality, particularly in
sub-Saharan Africa [1], has led to a paradigm shift in
treatment strategies. Since 2004, the World Health
Organization (WHO) recommends treatment with
artemisinin-based combination therapy (ACT) [2], and
ACT has been adopted as first-line treatment for
uncomplicated Plasmodium falciparum malaria in vir-
tually all African countries. Artemether-lumefantrine
(AL), the first fixed-dose ACT to be prequalified by the
WHO, has consistently shown PCR-corrected cure rates
> 95% against this species, with prompt resolution of
parasitaemia and fever, rapid gametocyte clearance and
good tolerance in populations of adults and children
[3-9], even when administered unsupervised [3,9-11].
Changes in parasite clearance in south-east Asia asso-
ciated with altered artemisinin sensitivity are not yet
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some declining responsiveness of P. falciparum infec-
tions to ACT (including AL) from non-Asian areas have
been reported [12]. While consumption of milk or food
enhances lumefantrine absorption, adequate exposure is
achieved with a standard African diet [13,14]. Due to
the short half-life of artemether [15], AL is administered
twice a day to ensure that infecting parasites are
exposed to artemether above the minimum effective
concentration [16] throughout most of their life cycle
[17]. A three-day regimen of AL is used to cover two
full parasite life asexual cycles [17] and thus maximize
efficacy [18]. High levels of adherence to this regimen
h a v eb e e nd e s c r i b e dw h e nA Li se m p l o y e di nt h ec o m -
munity [19].
Since AL was first licensed in 1999, it has been
recommended that the drug be dosed according to body
weight ranges, i.e. 5 to < 15 kg, 15 to < 25 kg, 25 to <
35 kg and > 35 kg [20]. This raises the question of
whether patients at the lower or upper end of a category
could be over- or underexposed to the drug. It is speci-
fically important to establish whether infants and chil-
dren in each weight category vary in terms of drug
exposure or outcomes (i.e. efficacy, safety and tolerabil-
ity) in relation to other weight groups. In the current
analysis, data from a randomized, multi-centre, investi-
gator-blinded study of AL involving 899 children in five
African countries were evaluated to compare the efficacy
and safety of AL between patients in the three body
weight ranges, and to examine the relationship between
age and body weight in this population.
Methods
Study design
This was a randomized, investigator-blinded, multi-cen-
tre trial undertaken to compare the efficacy, safety and
tolerability of AL using a six-dose regimen of the disper-
sible tablet formulation versus standard crushed tablets
in the treatment of acute uncomplicated P. falciparum
malaria in infants and children [21]. The study was con-
ducted at eight health care facilities in Benin, Kenya,
Mali, Mozambique and Tanzania/Zanzibar. Full details
of the study design and conduct have been published
previously [21]. This study has been registered at con-
trolled-trials.gov as NCT00386763.
Patients
The study population comprised infants and children
with microscopically confirmed acute uncomplicated P.
falciparum malaria. Key inclusion criteria were age ≤12
years, body weight ≥5k ga n d<3 5k g ,t h ep r e s e n c eo f
fever (≥37.5°C axillary or ≥38°C rectally) or a history of
fever in the preceding 24 h, P. falciparum malaria
(mono or mixed infection) with an asexual blood density
≥2,000/μL and < 200,000/μL, and the absence of severe
signs of complicated malaria as defined by WHO [22].
Key exclusion criteria included haemoglobin < 5 g/dL,
intake of anti-malarials other than chloroquine within
the previous 2 weeks (or up to a month if the drug
taken was AL), ongoing prophylaxis with drugs with
anti-malarial activity such as cotrimoxazole medication,
use of any drug known to influence cardiac function in
the preceding 4 weeks, corrected QT interval (QTc)
prolongation (males > 450 ms, females > 470 ms) or any
condition known to prolong QTc, and any serious
underlying disease.
Treatment
Eligible patients were randomly allocated to either dis-
persible or crushed tablets on a 1:1 ratio within each of
the three body weight dosing groups: 5 to < 15 kg, 15 to
<2 5k g ,o r2 5t o<3 5k g .A Lw a sa d m i n i s t e r e dt w i c e
daily for 3 days (six doses in total) with dosage deter-
mined according to body weight: one tablet per dose for
children 5 to < 15 kg, two tablets per dose for those 15
to < 25 kg, and three tablets per dose for those 25 to <
35 kg. One tablet contains 20 mg artemether and 120
mg lumefantrine. Dosages according to weight show
important variability between the different weight
groups, with the minimum and maximum levels of drug
intake both occurring in the 5-15 kg group, in which
artemether intake ranges from 1.33 to 4 mg/kg and
lumefantrine intake ranges from 8 to 24 mg/kg for each
dose administered. Variability in the other two weight
groups is much lower.
Patients were hospitalized during the three-day treat-
ment phase and followed on a weekly basis up until day
42 after initiation of treatment. Treatment was adminis-
tered under supervision and consumption of some food
or drink (e.g. breast milk, broth, or sweetened con-
densed milk) was recommended after dosing, to increase
drug absorption. Patients who vomited a dose within 1 h
of treatment were given a full replacement dose, but no
more than two doses were to be replaced during the
three-day treatment period.
Antipyretics, such as paracetamol, were used to con-
trol high fever. In the event of severe malaria or danger
signs, the patient was hospitalized and received intrave-
nous quinine. Rescue therapy according to local treat-
ment guidelines was also administered in cases of early
or late treatment failure [23] or if a replacement dose
was vomited within 2 h of administration.
Evaluation
Follow-up visits took place on days 3, 7, 14, 28, and 42
after enrolment or at any time point whenever the child
was sick. Patients who prematurely discontinued either
study drug or the study were scheduled for a final visit
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visit, the final outcome of the malaria episode was deter-
mined where possible. Vital signs and body temperature
were assessed at regular intervals during the study. A
12-lead electrocardiogram (ECG) was recorded at base-
line and on day 3 (6-10 h after the last dose) and QTc
calculated using Bazett’s and Fridericia’sQ Tc o r r e c t i o n
formulae. Clinical signs and symptoms were assessed at
baseline and before dosing, and any symptom that wor-
sened or started after baseline was recorded as a new
adverse event. An adverse event was defined as the
appearance or worsening of any undesirable sign, symp-
tom or medical condition occurring after starting the
study drug even if the event was not considered to be
related to study drug. An adverse event was considered
serious if it was fatal or life-threatening, resulted in per-
sistent or significant disability/incapacity or required
inpatient hospitalization or prolongation of existing hos-
pitalization. During the hospital stay and at every fol-
low-up visit, adverse events were assessed for severity
and association with study medication.
Thick and thin Giemsa-stained blood slides were pre-
pared before each dose was administered and at every
follow-up visit. Slides were examined by two indepen-
dent microscopists and considered negative if no para-
sites were seen after examination of 200 oil-immersion
fields in a thick blood film. Species determination was
made based on assessment of thin films. Blood samples
for PCR analysis were collected from every patient at
baseline and at days 14, 28 and 42. PCR was performed
centrally for all cases of recurrent parasitaemia after day
7 to distinguish recrudescence from reinfection.
Pharmacokinetic assessment
The methodology has been described previously [24]. In
brief, plasma concentrations of artemether and its major
active metabolite dihydroartemisinin (DHA) were mea-
sured in the first 184 patients (two blood samples each),
and lumefantrine concentration measured in the subse-
quent 625 patients (one blood sample each). For arte-
mether and DHA, the two samples were taken at 1 and
2 h post first treatment dose (i.e. anticipated time of
maximum concentration (Cmax)). Cmax was determined
from these two concentrations, whichever was larger for
a given patient. For determination of lumefantrine con-
centration, a sampling scheme was employed whereby
samples were taken 6 h after dose 3 in 10% of patients,
6 h after dose 5 in 10% of patients, 6 h after dose 6 in
50% of patients (i.e. the expected time to Cmax), 24 h
after dose 6 in 10% of patients, on day 7 in 10% of
patients and on day 14 in 10% of patients. A population
mean concentration-time curve was constructed by
averaging all concentrations available for specified
sampling intervals and taking the mean of the actual
sampling times in each interval. Cmax and AUC0-last
were derived from this population mean concentration-
time curve.
Study outcomes
The primary efficacy outcome was the 28-day PCR-cor-
rected parasitological cure rate, defined as the propor-
tion of patients with clearance of asexual parasitaemia
within 7 days of initiation of study treatment, without
recrudescence within 28 days and without use of rescue
medication. Secondary outcomes included the 14-day
and 42-day PCR-corrected parasitological cure rate, time
to parasite, fever and gametocyte clearance, and safety
and tolerability profiles.
Statistical analysis
The intent-to-treat (ITT) population comprised all ran-
domized patients with confirmed P. falciparum malaria
who received ≥1 full dose of study drug and underwent
≥1 relevant post-baseline efficacy assessment while on
treatment. The modified intent-to-treat (mITT) popula-
tion consisted of all ITT patients who completed 28
days with a valid PCR assessment (if parasitaemia was
present at day 28) or who were classified as treatment
failures (i.e. discontinued study drug and received rescue
treatment), but excluded patients who (i) received anti-
malarials or anti-malarial antibiotics before day 28 for
reasons other than rescue medication; (ii) had two repla-
cement doses and vomited a subsequent dose within 1 h
or vomited the replacement dose within 2 h; (iii)
switched to rescue medication therapy during the three-
day treatment period; or (iv) experienced a PCR-con-
firmed reinfection by day 28 or had missing/unclear
PCR results at day 28. The safety population comprised
all patients who received ≥1 dose of study medication
and underwent at least one post-baseline safety
assessment.
The primary end-point of 28-day PCR-corrected cure
rate was assessed in the mITT population and presented
with 95% confidence interval (CI) values. Time to parasite
and fever clearance was evaluated by Kaplan-Meier esti-
mates. Pharmacokinetic parameters are presented descrip-
tively. For this evaluation, data from patients receiving the
dispersible formulation of AL or standard crushed tablets
were combined since the two formulations have been
shown to be similar in terms of all measured efficacy,
safety and pharmacokinetic parameters [21].
Data are presented according to the following weight
groups: 5 to < 10 kg, 10 to < 15 kg (in order to further
characterise potential differences in response between
these two body weight groups despite the same dosing
regimen), 15 to < 25 kg and 25 to < 35 kg.
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Patient population
A total of 899 patients were randomized, of whom 168
weighed 5 to < 10 kg, 379 weighed 10 to < 15 kg, 289
patients (32.1%) weighed 15 to < 25 kg, and 63 patients
(7.0%) weighed 25 to < 35 kg. The ITT population
included 886 patients (98.6%) and the mITT population
included 812 patients (90.3%) (Table 1). The most fre-
quent reason for exclusion from the mITT population
was the absence of a day 28 parasite count in patients
who had not been previously classified as a failure (n =
68). Overall, 782/899 patients (87.0%) completed the
study. Baseline characteristics according to body weight
group are summarized in Table 2. There were 15
patients (1.7%) aged less than 6 months (13 in the
mITT population [1.6%]).
AL dosing and pharmacokinetics
In total, 866/899 patients (96.3%) completed the six-
dose treatment regimen. One hundred and eighty-four
patients provided two blood samples each for pharma-
cokinetic assessment of artemether and its major active
metabolite DHA, and 625 patients provided one sample
each for measurement of lumefantrine concentration. As
reported elsewhere [24], there were no clinically relevant
between-group differences in Cmax for artemether or
DHA; lumefantrine Cmax and AUC 0-last appeared higher
in the 15 to < 25 kg group compared to the 5 to < 15
kg body weight group, approximately in line with the
increase in dose, in particular for AUC after crushed
tablet. In view of potential concerns about exposure in
the smallest patients, a further pharmacokinetic sub-
group analysis was performed for patients weighing 5 to
<1 0k ga n d1 0t o<1 5k g( T a b l e3 ) .T h e s ep a t i e n t sa l l
received the same regimen of one tablet twice daily for
three days. Artemether and DHA Cmax were 2.15- to
3.4-fold higher in the 5 to < 10 kg body weight group
compared to the 10 to < 15 kg body weight group.
There were no apparent differences for lumefantrine
Cmax or AUC between the two body weight groups.
Age according to body weight dosing group
Figure 1 illustrates the distribution of age and weight
within the study population. As expected, there was a
progressively greater distribution of weight for a given
age in older children. Table 2 summarizes the mean age
in each body weight group. Analysis of age by body
weight showed that 80% (10-90th percentile) of patients
weighing 5 to < 15 kg, 15 to < 25 kg and 25 to < 35 kg
were aged 10-50 months, 46-100 months and 90-147
months, respectively.
Efficacy
Each body weight group showed a 28-day PCR-cor-
rected cure rate > 97% (5 to < 10 kg 97.2%, 10 to < 15
kg 98.8%, 15 to < 25 kg 97.8%, 25 to < 35 kg 98.3%).
The 28-day PCR-corrected cure rate was comparable
across all three body weight groups, with overlapping
95% CI values, i.e. there was no indication that outcome
was affected by body weight group (Table 4). PCR cure
rates at 14 days and 42 days were also similar in differ-
ent body weight groups (Table 4).
There was a tendency towards longer time to parasite
and fever clearance in the lower body weight groups
(Table 4). A meaningful assessment of gametocyte clear-
ance according to body weight group was not possible
due to the low number of patients with gametocytaemia
at baseline (n = 41).
Safety
The majority of adverse events were symptoms related
to malaria (either the initial infection or the recurrent
one). Across the total study population, the most fre-
quent adverse events were pyrexia (36.9%), cough
(24.2%), P. falciparum infection (20.8%) and vomiting
(16.8%), the majority of which could be attributed to
Table 1 Number of participants by study population
Body weight
Number of participants All 5 to < 15 kg 15 to < 25 kg 25 to < 35 kg
5 to < 10 10 to < 15
Randomized population 547 168 379 289 63
ITT population
a 535 164 371 288 63
mITT population
b 477 143 334 277 58
Safety population 547 168 379 289 63
Patients could have more than one reason for exclusion from the ITT and mITT populations.
a Reasons for exclusion from ITT population: no relevant post-baseline efficacy assessment (n = 12), no full dose of study medication taken (n = 9) and no P.
falciparum at baseline (n = 1)
b Reasons for exclusion from the mITT population were as for the ITT population, and additionally no day 28 parasite count without being a failure prior to day
28 (n = 68), vomiting of replacement dose or two replacements and subsequent vomiting (n = 16), reappearance of parasite but no valid PCR analysis until day
28 (n = 7), switch to rescue for other reasons (n = 4) and use of concomitant anti-malarials other than rescue medication (n = 4)
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cumulative rate of adverse events to day 42 was 74.4%,
69.9%, 67.8% and 61.9% in patients weighing 5 to < 10
kg, 10 to < 15 kg, 15 to < 25 kg and 25 to < 35 kg,
respectively. There was a decreasing incidence of
vomiting and pyrexia and an increasing incidence of
headache and P. falciparum infection with higher body
weight. The cumulative incidence of these adverse
events to day 42 in the 5 to < 10 kg, 10 to < 15 kg, 15
to < 25 kg and 25 to < 35 kg cohorts was, respectively:
vomiting, 32.1%, 16.4%, 11.4% and 3.2%; pyrexia, 42.3%,
38.3%, 34.9% and 23.8%; headache: 0.6%, 3.7%, 13.5%
and 19.0%; P. falciparum: 16.7%, 20.1%, 23.2% and
25.4%. Other than vomiting( n=7 5 ,8 . 3 % ) ,n oa d v e r s e
event was reported to have a suspected relation to study
drug in more than five patients. Serious adverse events
were rare, occurring in 1.4% patients (n = 13) overall:
4.8% in the 5 to < 10 kg group, 0.8% in the 10 to < 15
kg group, 0.7% in the 15 to < 25 kg group and none in
the 15 to < 25 kg group. In the 5 to < 10 kg group, ser-
ious adverse events (14 events in eight patients)
included two episodes of initially severe malaria and two
late malaria episodes on days 26 and 29 (one was a
PCR-confirmed reinfection; one had no PCR data avail-
able). No serious adverse events were suspected to be
related to study drug.
Study medication was discontinued due to adverse
events in 20 patients (2.2%). Vomiting was the most fre-
quent of these events (n = 17/22 adverse events). The
most frequent reason for discontinuation of the study
was adverse events (n = 70, 7.8%) and loss to follow-up
(n = 27, 3.0%). The type of adverse event leading to
study discontinuation was not recorded, but the proto-
col stipulated that any patient who required a second
replacement dose of study drug was to be discontinued.
T h r e ed e a t h so c c u r r e d :o n eo nd a y3 1d u et oan e w
and severe P. falciparum infection after clearing para-
sites within 24 h of the initial infection (5 to < 10 kg
group), one on day 3 due to an unspecified infection
Table 2 Baseline characteristics (safety population)
Baseline Characteristics Body weight
5 to < 10 kg
(n = 168)
10 to < 15 kg
(n = 379)
15 to < 25 kg
(n = 289)
25 to < 35 kg
(n = 63)
Body weight (kg)
Mean(SD) 8.3 (1.1) 12.1 (1.4) 18.1 (2.6) 28.1 (3.0)
Median (range) 8.5 (5.0-9.9) 12.0 (10.0-14.7) 17.8 (15.0-24.5) 27.0 (25.0-34.0)
Female gender, n (%) 86 (51.2) 182 (48.0) 136 (47.1) 16 (25.4)
Age, months
Mean (SD) 14.4 (6.7) 35.9 (13.5) 71.7 (22.4) 119.3 (20.5)
Median (range) 14 (0.0-42)
a 35 (6-70) 71 (31-148) 122 (78-152)
Temperature,°C
Mean (SD) 37.9 (1.2) 38.1 (1.1) 37.9 (1.0) 38.0 (1.0)
Parasite density, /μL
Mean (SD) 49,571 (51,536) 53,921 (57,572) 40,974 (41,763) 21,850 (24,867)
Median (range) 31,937 35,400 26,640 13,040
(0-228,000) (520-628,571) (2,039-192,610) (1,581-109,720)
a Start of treatment in one patient was recorded as day 21 after documented date of birth
Table 3 AL dosing and pharmacokinetic parameters in
patients weighing 5 to < 10 kg or 10 to < 15 kg
Body
weight
5t o<1 0
kg
10 to < 15
kg
Artemether & dihydroartemisinin
(DHA)
Dispersible tablet N = 17
1 N=3 5
2
Total dose artemether (mg/kg) 14.8 ± 2.57 10.0 ± 1.30
Cmax artemether (ng/mL) 372 ± 251 110 ± 97.7
Cmax DHA (ng/mL) 107 ± 76.6 38.2 ± 42.4
Crushed tablet N = 18
3 N=3 7
Total dose artemether (mg/kg) 14.7 ± 1.94 10.0 ± 1.28
Cmax artemether (ng/mL) 295 ± 214 137 ± 111
Cmax DHA (ng/mL) 89.9 ± 83.5 36.6 ± 28.7
Lumefantrine
Dispersible tablet N = 24 N = 78
Total dose lumefantrine (mg/kg) 90.4 ± 9.46 60.4 ± 7.37
Cmax (μg/mL) 6.55 5.55
AUC0-last (μg·h/mL) 550 393
Crushed tablet N = 26 N = 75
Total dose lumefantrine (mg/kg) 88.6 ± 13.1 59.5 ± 6.87
Cmax (μg/mL) 5.50 6.29
AUC0-last (μg·h/mL) 578 558
Data are mean ± SD;
1 N = 18 for DHA;
2 N = 34 for DHA;
3 N = 19 for DHA
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Table 4 Efficacy outcomes by body weight group
Body weight
Efficacy outcomes 5 to < 10 kg 10 to < 15 kg 15 to < 25 kg 25 to < 35 kg
14-day PCR cure
a
n/N 140/143 334/334 277/277 58/58
% 97.9 100.0 100.0 100.0
95% CI (%) 94.0-99.6 97.9-100.0 98.7-100.0 90.8-100.0
28-day PCR cure
a
n/N 139/143 330/334 271/277 57/58
% 97.2% 98.8% 97.8% 98.3%
95% CI (%) 93.0-99.2% 97.0-99.7% 95.3-99.2% 90-8-100.0%
42-day PCR cure
a
n/N 123/129 284/290 227/237 50/53
% 95.3 97.9 95.8 94.3
95% 90.2-98.3 95.6-99.2 92.4-98.0 84.3-98.8
Kaplan Meier estimates of parasite clearance time, h
b
N 164 371 288 63
Median 35.6 35.0 25.8 25.8
Interquartile range 24.0-36.1 23.9-36.1 23.8-35.9 23.9-35.7
Mean (SE) 35.0 (1.2) 32.8 (1.0) 31.7 (1.1) 30.8 (1.6)
Kaplan Meier estimates of fever clearance time, h
b
N 164 369 288 63
Median 8.2 7.8 7.8 7.7
Interquartile range 7.7-35.0 7.5-23.6 7.6-23.4 7.4-8.5
Mean (SE) 44.4 (9.1) 26.5 (3.5) 30.5 (6.4) 11.5 (1.4)
a mITT population
b ITT population
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AL due to vomiting on day 2, at which point the patient
was free of infection (5 to < 10 kg group) and one on
day 7 due to haemorrhage after scarification by a witch
doctor (10 to < 15 kg group). No death was suspected
to be related to the study drug.
Discussion
In this large population of African infants and children
with uncomplicated falciparum malaria, the high efficacy
of AL was confirmed across all body weight groups. The
28-day PCR-corrected cure rate, the primary endpoint,
exceeded 97% in each body weight group with no indi-
cation that outcome differed between groups. These
findings confirm that a fixed-dose strategy according to
certain body weight groups (i.e. use of discrete dosing
for a continuous weight variable) does not result in
under-dosing with reduced efficacy or, alternatively,
overdosing and risk of toxicity, at the extremes of each
body weight window. Thus, the current body-weight
dosing recommendations for AL appear appropriate.
Specifically, dosing advice for the lowest body weight
g r o u p( 5t o<1 5k g )a n d ,i n d e e d ,f o rt h es m a l l e s t
patients within this category (5 to < 10 kg) is adequate,
as confirmed by the efficacy and safety findings. Addi-
tionally, analysis of age by body weight group in this
population of children from sub-Saharan African coun-
tries showed there to be only a minor overlap of age
ranges between body weight groups based on the 10-
90th percentiles.
In endemic areas, effective anti-malarial treatment is
particularly critical in young children, who are in the
process of acquiring partial immunity and present with
high parasite densities and acute clinical episodes that
can progress rapidly into severe, life-threatening malaria
[2]. AL exposure was highest in the smallest children
with body weight 5 to < 10 kg, but these results should
be interpreted with caution due to the small sample size
in this body weight group. Plasma levels of artemether,
DHA and lumefantrine in all body weight groups (even
in the smallest children, weighing 5 to < 10 kg)
remained within the ranges reported in studies of adult
patients [3,5,24,25]. Lumefa n t r i n ee x p o s u r ew a sa p p a r -
ently unchanged in the smallest (5 to < 10 kg) children.
It is reassuring that there was no trend to any age group
having reduced exposure to artemether, DHA or lume-
fantrine. These pharmacokinetic analyses did not, how-
ever, undergo formal statistical comparisons, so
conclusions must be tentative. The tendency towards
longer time to parasite and fever clearance in the lower
body weight groups may be partly explained by the
lower immunity of younger children. Moreover differ-
ences in time to parasite and fever clearance between
body weight groups need to be interpreted with caution
since the measurements were scheduled to take place at
8, 24, 36, 48, and 60 h after the start of treatment, i.e.
there was no continuous monitoring. This may have
magnified differences between values since, for example,
fever clearance at 50 h will only have been recorded at
60 h. Regardless of these methodological issues, how-
ever, it is important to be aware that in malaria-endemic
areas, infants may be particularly vulnerable to slower
clearance rates for parasitaemia. This is because they
may be starting to acquire protective immunity, and as
a result the likelihood of detecting resistant parasites
may be higher in this age group. Delayed clearance
times have been phenotypically linked to artemisinin
resistance in the Thai-Cambodian border [26]. However,
such cases may not necessarily represent a true emer-
gence of parasite resistance to the drug because due to
this lower immunity, infants can present with clinical
evidence of malaria despite a relatively low parasite
count i.e. fewer parasites may induce symptoms in
infants than in older children. Nevertheless, the rele-
vance of this finding needs to be reassessed to further
clarify its potential impact. The current study excluded
patients below 5 kg in weight, in accordance with WHO
guidelines [2], since the safety and efficacy of ACT
remains to be confirmed in this particular population.
There were, however, 15 patients (1.7%) aged less than
six months but weighing more than 5 kg included in the
study.
Tolerability of AL was good, with no new safety con-
cerns observed. The most frequently reported events
were symptoms of malaria i.e. pyrexia, vomiting, cough
and P. falciparum infection. The higher rate of vomiting
and pyrexia in smaller children is expected, and in
accordance with previous reports [27] it is possible that
the increased incidence of headache in the higher body
weight groups may have reflected the fact that smaller
children are less likely to verbalize symptoms such as
headache than the older patients. Cough tends to occur
more frequently in young (< 5 years) patients with
malaria [28] and the relatively high incidence reported
here (24.2%) reflects the predominance of younger chil-
dren in our population. P. falciparum infection reported
as an adverse event most likely represents new infec-
tions, due to the long follow-up period, i.e. 42 days. The
assessment of adverse events in cases of malaria, how-
ever, remains challenging because of the high back-
ground of malaria signs and symptoms [29]. Here,
clinical assessment prior to the first dose of AL was per-
formed in an attempt to make the adverse event report-
ing as robust as possible, with only those events which
worsened or first occurred after the start of treatment
being considered treatment-emergent adverse events.
Nevertheless, although ACTs are universally regarded as
very safe and tolerable drugs, the possibility that serious
Bassat et al. Malaria Journal 2011, 10:369
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Page 7 of 9and non-serious adverse events are more frequently
detected with the widespread use of the drug should
always be considered.
The study methodology was robust. The population
was large and the age distribution, in which approxi-
mately 60% of patients fell into the 5 to < 15 kg body
weight group, reflects the fact that young children are
t h em o s tv u l n e r a b l et om a l a r i am o r b i d i t ya n dm o r t a l i t y
[30]. As specified in the protocol, artemether and lume-
fantrine plasma concentration was determined in sepa-
rate subpopulations at different stages of the trial, but
numbers were adequate for reliable estimations of phar-
macokinetic parameters. The statistical methodology
was sound, with the percentage of patients excluded
from the mITT population (9.7%) being in the range of
the pre-specified maximum of 10%.
Conclusion
The efficacy of AL in treating uncomplicated falciparum
malaria was similar across body weight dosing groups in
infants and children, with no clinically relevant differ-
ences in safety or tolerability even when the lowest body
weight group was further divided into patients weighing
only 5 to < 10 kg. Analysis of age by body weight group
in this population of children from sub-Saharan African
countries indicates that the AL dosage scheme is appro-
priate even in the youngest children.
Acknowledgements
With grateful thanks to all patients and local staff, Novartis personnel (A
Coovadia, P Ibarra de Palacios, A-C Marrast, N Mulure and M Cousin); Peter
Kremsner and Klaus Dietz from the University of Tübingen for their
participation in the Data Monitoring Board, Martina Wibberg, Tanja
Widmayer and Jürgen Lilienthal, and members of the B2303 Study Group: C
Membi, A Mohammed, A Abdallah (Ifakara Health Research and
Development Centre, Dar es Salaam, Tanzania); A Björkman, G Rotllant
Estelrich, H Makame and M Msellem (Zanzibar Malaria Research Unit of the
Karolinska Institute, Tanzania); PK Klouwenberg, A Salim (Kenya Medical
Research Institute, Kilifi, Kenya); D Ahounou, D Bonou, A Massougbodji, M
Bancolé, T Hounhouedo, C Agbowaï (Centre de Recherche Entomologique
de Cotonou, Cotonou, Bénin); P Alonso (CRESIB, Barcelona Centre for
International Health Research); M Renom, I Mandomando and E Macete
(CISM, Centro de Investigação em Saúde de Manhiça, Manhiça,
Mozambique); V Owira, M Polhemus, N Otsyula (Walter Reed Project/Kenya
Medical Research Institute, Kisumu, Kenya); A Djimde, OB Traore, M Tekete, ZI
Traore, N Diallo, S Dama, N Ouologuem, O Doumbo (Malaria Research and
Training Center, University of Bamako, Bamako, Mali). Medical writing
support was provided by Caroline Dunstall with funding from Novartis
Pharma AG.
Author details
1Barcelona Centre for International Health Research (CRESIB), Hospital Clínic,
Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de
Barcelona, Rosselló 132, 4°, 08036 Barcelona, Spain.
2Centro de Investigação
em Saúde de Manhiça (CISM), Manhiça, Mozambique.
3Centre de Recherche
Entomologique de Cotonou, Cotonou, Benin.
4Ifakara Health Research and
Development Centre, Dar es Salaam, Tanzania.
5Malaria Research and
Training Center, University of Bamako, Bamako, Mali.
6Division of Global
Health, Dept of Public Health Sciences, Karolinska Institutet, Unit of Infectious
Diseases, Dept of Medicine, Karolinska Institutet/Karolinska University
Hospital, Stockholm, Sweden and Zanzibar Malaria Research Unit of the
Karolinska Institutet, Zanzibar, Tanzania.
7Kenya Medical Research Institute,
Kilifi, Kenya.
8Kenya Medical Research Institute/Center for Disease Control,
Kisumu, Kenya.
9Medicines for Malaria Venture (MMV), Geneva, Switzerland.
10Novartis Pharma AG, Basel, Switzerland.
11Novartis Pharma AG, Mushin,
Lagos, Nigeria.
12Novartis Pharma Services AG, Africa Re Centre, Hospital
Road, Nairobi, Kenya.
13Walter Reed Project, Kenya Medical Research Institute,
Kisumu, Kenya.
Authors’ contributions
All authors contributed to the design of the study and assisted with data
interpretation. QB, CM, RG, SM, AN, JL, HM, AM, MB, PO, DU and BO
coordinated the study and supervised the enrolment and follow-up of
patients. VW provided biostatistical support and GL conducted the
pharmacokinetic evaluation. ON and CK acted as medical advisors. All
authors participated in the preparation of the manuscript and approved the
final version.
Competing interests
Novartis Pharma AG funded the study and provided editorial support for the
manuscript. QB has received speaker fees and payments from Novartis to
attend meetings relating to this trial. VW, ON, GL and CK are employees of
Novartis. DU is employed by Medicines for Malaria Venture (MMV). The other
authors have no conflicts of interest to declare.
Received: 8 July 2011 Accepted: 16 December 2011
Published: 16 December 2011
References
1. Trape JF: The public health impact of chloroquine resistance in Africa.
Am J Trop Med Hyg 2001, 64(1-2 Suppl):12-17.
2. WHO: Guidelines for the treatment of malaria , Second, World Health
Organization web site. [Available at http://www.who.int/malaria/
publications/atoz/9789241547925/en/index.html Accessed March 29, 2010].
3. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J,
Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F,
Guthmann JP: Supervised versus unsupervised intake of six-dose
artemether-lumefantrine for treatment of acute, uncomplicated
Plasmodium falciparum malaria in Mbarara, Uganda: a randomized trial.
Lancet 2005, 365:1467-1473.
4. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L,
Gathmann I, Mull R, Brockman A, White NJ, Nosten F: Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum malaria.
Trans R Soc Trop Med Hyg 2000, 94:545-548.
5. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U,
Gathmann I, Mull R, Bakshi R: A clinical and pharmacokinetic trial of six
doses of artemether-lumefantrine for multidrug-resistant Plasmodium
falciparum malaria in Thailand. Am J Trop Med Hyg 2001, 64:247-256.
6. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K,
Hunt P, De Palacios PI: Efficacy and safety of the six-dose regimen of
artemether-lumefantrine in pediatrics with uncomplicated Plasmodium
falciparum malaria: a pooled analysis of individual patient data. Am J
Trop Med Hyg 2006, 74:991-998.
7. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-
Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ: Combination therapy
for uncomplicated falciparum malaria in Ugandan children: a
randomized trial. JAMA 2007, 297:2210-2219.
8. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI:
Efficacy and safety of artemether-lumefantrine (Coartem®) tablets (six-
dose regimen) in African infants and children with acute, uncomplicated
malaria. Trans R Soc Trop Med Hyg 2005, 99:459-467.
9. Mutabingwa T, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C,
Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine +
sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-
lumefantrine for outpatient treatment of malaria in Tanzanian children:
a four-arm randomised effectiveness trial. Lancet 2005, 365:1474-1480.
10. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D,
Bergqvist Y, Gil JP, Premji Z, Björkman A, Mårtensson A: Efficacy and
effectiveness of artemether-lumefantrine after initial and repeated
treatment in children < 5 years of age with acute uncomplicated
Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin
Infect Dis 2011, 52:873-882.
Bassat et al. Malaria Journal 2011, 10:369
http://www.malariajournal.com/content/10/1/369
Page 8 of 911. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D,
Bergqvist Y, Gil JP, Premji Z, Mårtensson A: Effectiveness of artemether-
lumefantrine provided by community health workers in under-five
children with uncomplicated malaria in rural Tanzania: an open label
prospective study. Malar J 2011, 10:64.
12. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, Frühauf H,
Schaub B, Pfeil J, Peshu J, Hanpithakpong W, Rippert A, Juma E, Tsofa B,
Mosobo M, Lowe B, Osier F, Fegan G, Lindegårdh N, Nzila A, Peshu N,
Mackinnon M, Marsh K: Declining responsiveness of plasmodium
falciparum infections to artemisinin-based combination treatments on
the Kenyan coast. PLoS One 2011, 6:e26005.
13. Borrmann S, Sallas WM, Machevo S, González R, Björkman A, Mårtensson A,
Hamel M, Juma E, Peshu J, Ogutu B, Djimdé A, D’Alessandro U, Marrast AC,
Lefèvre G, Kern SE: The effect of food consumption on lumefantrine
bioavailability in African children receiving artemether-lumefantrine
crushed or dispersible tablets (Coartem) for acute uncomplicated
Plasmodium falciparum malaria. Trop Med Int Health 2010, 15:434-441.
14. Premji ZG, Abdulla S, Ogutu B, Ndong A, Falade CO, Sagara I, Mulure N,
Nwaiwu O, Kokwaro G: The content of African diets is adequate to
achieve optimal efficacy with fixed-dose artemether-lumefantrine: a
review of the evidence. Malar J 2008, 7:244.
15. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and
pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999,
37:105-125.
16. Kokwaro G, Mwai L, Nzila A: Artemether/lumefantrine in the treatment of
uncomplicated falciparum malaria. Expert Opin Pharmacother 2007,
8:75-94.
17. White NJ: Antimalarial pharmacokinetics and treatment regimens. Br J
Clin Pharmacol 1992, 34:1-10.
18. Van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A,
Luxemburger C, White NJ, Nosten F, Looareesuwan S: Efficacy of six doses
of artemether-lumefantrine (benflumetol) in multidrug-resistant
Plasmodium falciparum malaria. Am J Trop Med Hyg 1999, 60:936-942.
19. Kabanywanyi AM, Lengeler C, Kasim P, King’eng’ena S, Schlienger R,
Mulure N, Genton B: Adherence to and acceptability of artemether-
lumefantrine as first-line anti-malarial treatment: evidence from a rural
community in Tanzania. Malaria J 2010, 9:48.
20. Coartem
®/Riamet
® Basic Prescribing Information. Novartis Pharma AG ,
Last updated September 2007.
21. Abdulla S, Sagara I, Borrmann S, D’Alessandro U, González R, Hamel M,
Ogutu B, Mårtensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat Q,
Juma E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M, Lefèvre G,
Ubben D, Premji Z: Efficacy and safety of artemether-lumefantrine
dispersible tablets compared with crushed commercial tablets in African
infants and children with uncomplicated malaria: a randomised, single-
blind, multicentre trial. Lancet 2008, 372:1819-1827.
22. World Health Organization: Severe falciparum malaria. Trans R Soc Trop
Med Hyg 2000, 94:S1-S90.
23. World Health Organization: Assessment and monitoring of antimalarial
drug efficacy for the treatment of uncomplicated falciparum malaria.
2003 [http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/
], [Accessed June 22, 2008].
24. Djimdé AA, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I,
Lefèvre G, Borrmann S: Pharmacokinetic and pharmacodynamic
characteristics of artemether-lumefantrine dispersible tablet in African
children with uncomplicated malaria. Antimicrob Agents Chemother .
25. Ashley EA, Stepniewska K, Lindegårdh N, McGready R, Annerberg A,
Hutagalung R, Singtoroj T, Hla G, Brockman A, Proux S, Wilahphaingern J,
Singhasivanon P, White NJ, Nosten F: Pharmacokinetic study of
artemether-lumefantrine given once daily for the treatment of
uncomplicated multidrug-resistant falciparum malaria. Tropical Med Int
Health 2007, 12:201-208.
26. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Artemisinin
Resistance in Cambodia 1 (ARC1) study consortium. Evidence of
artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008,
359:2619-2620.
27. Rogier C, Ly AB, Tall A, Cissé B, Trape JF: Plasmodium falciparumclinical
malaria in Dielmo, a holoendemic area in Senegal: no influence of
acquired immunity on initial symptomatology and severity of malaria
attacks. Am J Trop Med Hyg 1999, 60:410-420.
28. Idro R, Bitarakwate E, Tumwesigire S, John CH: Clinical manifestations of
severe malaria in the highlands of southwestern Uganda. Am J Trop Med
Hyg 2005, 72:561-567.
29. Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, Maiteki-Sebuguzi C,
Clark TD, Nzarubara B, Njama-Meya D, Mpimbaza A, Rosenthal PJ,
Kamya MR, Wabwire-Mangen F, Dorsey G, Talisuna AO: Monitoring
antimalarial safety and tolerability in clinical trials: a case study from
Uganda. Malar J 2008, 7:107.
30. Samba EM: The burden of malaria in Africa. Afr Health 1997, 19:17.
doi:10.1186/1475-2875-10-369
Cite this article as: Bassat et al.: Similar efficacy and safety of
artemether-lumefantrine (Coartem
®®) in African infants and children
with uncomplicated falciparum malaria across different body weight
ranges. Malaria Journal 2011 10:369.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bassat et al. Malaria Journal 2011, 10:369
http://www.malariajournal.com/content/10/1/369
Page 9 of 9